Adam bashed my #1 long biotech holding last year. The perspective he provided in the article was remarkably similar to ANX. Here is a link so you can read his article.
Since he published the bashing, (did I say bashing? I meant objective report) his views have been soundly rejected by the market and by medical professionals. I doubled my long position since then and the stock has rebased higher by 41%.
I know Cramer's organization has a lot of fans, but if you look at Adam F's track record, it seems to serve a purpose, just like the rest of the financial media.
I'm trading ANX on the business fundamentals and chart technicals.